Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial

Abstract Relapse remains a major challenge for high-risk acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In our first-in-human Phase I trial (ChiCTR-1900022795), we have demonstrated that third-party donor-derived double-negative T cell...

Full description

Bibliographic Details

Published in:	Experimental Hematology & Oncology
Main Authors:	Guangyu Sun, Xingchi Chen, Tianzhong Pan, Kaidi Song, Haicun Xie, Meijuan Tu, Xiang Wan, Wen Yao, Yaxin Cheng, Ziwei Zhou, Dongyao Wang, Yongsheng Han, Baolin Tang, Liming Yang, Xiaoyu Zhu
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	Double negative T cell Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation Relapse Adoptive cellular therapy Immune modulator
Online Access:	https://doi.org/10.1186/s40164-025-00680-1